Antiphospholipid antibodies and antiphospholipid syndrome
Antiphospholipid antibodies and antiphospholipid syndrome
复制标题
抗磷脂抗体和抗磷脂综合征
DOI：
--
复制
发表时间：
1995
影响因子：
5.1
通讯作者：
G. Hughes
中科院分区：
文献类型：
--
作者：
M. Khamashta;G. Hughes
自从抗磷脂综合征（APS）的详细临床描述以来，已经过去了十多年。血栓形成是该综合征的主要并发症，可影响各种大小的血管;一致的组织病理学病变是无炎症的温和血栓。动物模型为APS的临床和致病方面提供了重要的新数据。关于所谓的辅因子β 2-糖蛋白I的生物学的新数据现在是可用的。显然，磷脂抗原的呈递方式似乎很重要，β 2-糖蛋白I可能起重要作用。关于治疗，进一步证实抗磷脂抗体相关血栓形成患者需要长期抗凝治疗并维持较高的国际标准化比值，以防止复发。
More than a decade has gone by since the detailed clinical description of antiphospholipid syndrome (APS). Thrombosis, the main complication of the syndrome, can affect vessels of all sizes; the consistent histopathologic lesion is a bland thrombus without inflammation. Animal models are providing important new data on clinical and pathogenic aspects of APS. New data on the biology of the so-called cofactor ß2-glycoprotein I is now available. Clearly, the mode of presentation of the phospholipid antigen appears significant, and ß2-glycoprotein I may play an important part. Regarding treatment, there is further confirmation that long-term anticoagulation therapy with maintenance of a high international normalized ratio is needed in patients with antiphospholipid antibody-associated thrombosis to prevent recurrences.